Show simple item record

dc.contributorBadawi, M.A.EN
dc.contributorWagdy, E.EN
dc.contributorNasr, M.EN
dc.contributorEtman, M.A.EN
dc.contributorEl Khordagui, L.K.EN
dc.contributorKhalil, S.A.H.EN
dc.date.accessioned2014-06-17T10:23:12Z
dc.date.available2014-06-17T10:23:12Z
dc.date.issued2013EN
dc.identifier.issn1020-3397EN
dc.identifier.otherEN
dc.identifier.urihttp://www.who.int/iris/handle/10665/118606
dc.description1-10EN
dc.description.abstractConcerns have raised regarding the postmarketing quality of generic drugs. This study assessed the pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol tablets in 24 healthy male volunteers in a single-dose, open, randomized, two-period crossover study under fasting conditions. Blood samples were collected for 24 h post dosing and assayed for atenolol using HPLC. Blood pressure and heart rate were measured at baseline and throughout blood sampling. The mean plasma concentration-time curves for both products were similar. Pharmacokinetic and statistical analysis indicated bioequivalence based on the mean ratios of log-transformed Cmax and AUC values. Both products had similar time courses of pharmacodynamic activity with a significant fall in blood pressure and heart rate [‎maximum after ~5 h]‎ followed by a gradual increase towards baseline. Both products were well tolerated. Both atenolol products were bioequivalent in the postmarketing setting and can be used interchangeably in clinical practiceEN
dc.language.isoenEN
dc.titlePostmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in EgyptEN
dc.relation.ispartofjournalEMHJ - Eastern Mediterranean Health Journal, 19 (‎Supp.2)‎, 1-10, 2013


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(‎s)‎

Show simple item record